Research
Hormonal
Obesity, particularly abdominal-visceral obesity, is a primary risk factor for metabolic syndrome and cardiovascular disease through mechanisms involving insulin resistance, chronic inflammation, and dyslipidemia.
Maintaining a healthy weight, particularly around the abdomen, is crucial for preventing metabolic syndrome and heart disease. This involves managing caloric intake, increasing physical activity, and monitoring blood pressure and lipid levels.
StrongSupportsVERY_HIGH confidence
Obesity, especially abdomino-visceral, is associated with certain pathogenic factors that contribute to normal glucose homeostasis: high plasma levels of increased hepatic glycogenesis, and free fatty acids, insulin resistance.
Why this rating
Based on extensive physiological descriptions and multiple epidemiological studies across South America.
Source
Overweight and obesity: a review of their relationship to metabolic syndrome, cardiovascular disease, and cancer in South America
Laura Rosana Aballay et al. · Nutrition Reviews · 2013
DOI 10.1111/j.1753-4887.2012.00533.x
narrative_review · n=6000Cited 188×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Regular moderate-to-intense physical activity (>1,500 METs) reduces the risk of obesity by 40–65% and attenuates cardiovascular risk factors through anti-inflammatory effects and increased nitric oxide production.Good
- Obesity is a risk factor for several cancers, including colon, pancreas, kidney, prostate, breast, and endometrium, potentially through mechanisms involving chronic inflammation, insulin resistance, and adipocytokine production.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →